KRM AYURVEDA IPO
Quick Overview of KRM AYURVEDA IPO
| IPO Period | 21st – 23rd Jan 2026 |
|---|---|
| Listing on | 29 Jan 2026 |
| Price Band | ₹128 – ₹135 |
| Lot Size & Minimum Investment | 1000 shares (₹135,000 at upper price band) |
| Total Issue Size | ₹77.49 Crores |
Crucial Dates for the KRM AYURVEDA IPO
- Opening Date: 21 Jan 2026
- Closing Date: 23 Jan 2026
- UPI Payment Deadline: 23 Jan 2026 (5 PM)
- Allotment Announcement: 27 Jan 2026
- Refund Processing: 28 Jan 2026
- Demat Credit: 28 Jan 2026
- Stock Market Listing: 29 Jan 2026
- Mandate Validity End: 07 Feb 2026
- Anchor Investor Lock-in Release (50%): 23 Feb 2026
- Anchor Investor Lock-in Release (Remaining): 24 Apr 2026
*Dates may be revised as per official updates.
Unveiling KRM AYURVEDA: A Deep Dive into its Business
Founded in September 2019 and subsequently converted into a public limited company in December 2024, KRM AYURVEDA Limited is a prominent player in the dynamic AYUSH healthcare segment. Promoted by Mr. Puneet Dhawan and Mrs. Tanya Dhawan, the company distinguishes itself by seamlessly integrating classical Ayurvedic knowledge with contemporary clinical practices. This unique approach allows KRM AYURVEDA to deliver holistic and effective healthcare solutions.
The company operates an expansive network of hospitals and clinics strategically located across various cities in India. Beyond its physical infrastructure, KRM AYURVEDA has embraced modern healthcare delivery methods through robust telemedicine services. This digital outreach capability significantly extends its patient base, enabling both domestic and international patient consultations and treatment. Initially, KRM AYURVEDA carved a niche as a specialized kidney care provider, building a strong foundation of expertise and trust in this critical area.
Demonstrating its commitment to comprehensive healthcare, the company has successfully broadened its treatment portfolio. Today, it addresses a wide spectrum of chronic and lifestyle-related conditions, including intricate liver disorders, diabetes management, fatty liver conditions, arthritis, and a robust focus on preventive healthcare. KRM AYURVEDA’s patient-centric business model is built on a multi-modal approach, encompassing in-person consultations, hospital-based care for more intensive treatments, and convenient tele-consultation services. Revenues are primarily generated through the provision of healthcare services, specialized wellness programs, and various associated treatment offerings. The company’s market positioning is bolstered by its specialized Ayurvedic expertise, an ever-expanding physical and digital footprint, the development of personalized treatment protocols tailored to individual patient needs, and a steadily growing brand reputation in the holistic healthcare sector.
IPO Funding Structure and Objectives
| Total Funds Raised | ₹77.49 Crores |
|---|---|
| Fresh Issue Component | ₹77.49 Crores |
| Offer for Sale Component | ₹0 Crores |
The KRM AYURVEDA IPO is structured entirely as a Fresh Issue, meaning all the capital raised will directly flow into the company’s coffers. This significant inflow of funds is earmarked for specific strategic initiatives aimed at bolstering the company’s growth trajectory and strengthening its operational capabilities. The absence of an Offer for Sale component underscores the company’s intent to utilize the entirety of the proceeds for its business expansion and working capital needs, rather than for existing shareholders to dilute their holdings.
Strategic Allocation of IPO Proceeds
The capital raised through the KRM AYURVEDA IPO is intended for several key strategic purposes, each vital for the company’s continued expansion and operational efficiency:
| Objective | Amount (INR Crores) | Allocation % |
|---|---|---|
| Capital Expenditure for Telemedicine Facilities | 13.67 | 17.64% |
| CRM Software & Hardware Infrastructure | 1.42 | 1.83% |
| Human Resources | 5.44 | 7.02% |
| Repayment / Prepayment of Loan | 12.50 | 16.13% |
| Working capital requirements | 18.00 | 23.23% |
| General corporate purposes | 26.46 | 34.15% |
A significant portion of the funds, approximately 17.64%, is allocated towards enhancing capital expenditure for telemedicine facilities. This investment will expand KRM AYURVEDA’s digital healthcare infrastructure, allowing it to reach more patients nationally and internationally, and improve the quality and accessibility of its remote consultation services. Further strengthening its technological backbone, a smaller but crucial amount is set aside for CRM software and hardware infrastructure, which will streamline patient management, enhance customer service, and improve operational efficiency.
Investing in its most valuable asset, human resources, accounts for 7.02% of the proceeds. This allocation will support talent acquisition, training, and retention, ensuring the company maintains a highly skilled team of Ayurvedic practitioners and support staff. Furthermore, 16.13% of the funds are designated for the repayment or prepayment of existing loans, which will help reduce the company’s debt burden and improve its financial health. A substantial 23.23% is allocated to meet working capital requirements, essential for managing day-to-day operations, inventory, and ensuring smooth business continuity. Finally, a significant portion, 34.15%, is reserved for general corporate purposes, providing flexibility for future strategic initiatives, unforeseen exigencies, and overall business growth.
Distinctive Advantages of KRM AYURVEDA
KRM AYURVEDA possesses several competitive strengths that position it favorably within the healthcare industry:
- Integrated Ayurvedic Healthcare Model: The company successfully blends traditional Ayurvedic hospitals and clinics with modern telemedicine services. This hybrid model offers patients flexibility in accessing care, combining the efficacy of in-person treatments with the convenience of remote consultations, thereby expanding its reach and enhancing patient engagement.
- Strong Promoter Experience and Domain Knowledge: The leadership team, particularly the promoters Mr. Puneet Dhawan and Mrs. Tanya Dhawan, brings deep domain expertise in Ayurveda. This experience is critical in navigating the complexities of the AYUSH sector, fostering trust, and guiding the company’s strategic vision and clinical protocols.
- Specialised Expertise in Chronic and Lifestyle Disease Management: KRM AYURVEDA has developed significant proficiency in managing chronic and lifestyle-related ailments, a growing healthcare challenge globally. By focusing on conditions like liver disorders, diabetes, and arthritis, the company addresses a large and underserved patient demographic with specialized Ayurvedic solutions.
- Growing Physical Presence with Global Tele-Reach: The company boasts an expanding network of physical clinics and hospitals across multiple Indian states. Complementing this, its robust telemedicine platform provides global tele-reach, allowing KRM AYURVEDA to cater to an international clientele and tap into diverse markets.
- Increasing Brand Recognition in Holistic Healthcare: Through its patient-centric approach and effective treatment outcomes, KRM AYURVEDA is steadily building a reputable brand in the direct-to-consumer (D2C) and holistic healthcare segments. This growing recognition is crucial for attracting new patients and fostering long-term loyalty in a competitive market.
Key Considerations for Potential Investors
While KRM AYURVEDA presents compelling strengths, potential investors should also be aware of certain risk factors:
- High Dependence on North India for Revenues: A significant portion of the company’s revenues is generated from its operations in North India. This geographical concentration could expose KRM AYURVEDA to regional economic downturns, changes in local regulatory landscapes, or intensified competition within that specific market, potentially impacting its overall revenue stability.
- Asset-Light Operations with Leased Premises: The company primarily operates its hospitals and clinics on leased premises rather than owning them. While an asset-light model offers flexibility and reduces initial capital outlay, it also entails reliance on lease agreements, potential rent escalations, and a lack of long-term asset appreciation, which could affect operational costs and long-term stability.
- Working-Capital Intensive Business with Negative Cash Flows: The healthcare sector, especially one with an expanding physical and digital footprint, can be working-capital intensive. KRM AYURVEDA has a history of negative cash flows, indicating that its operating activities may consume more cash than they generate. This necessitates continuous external funding or careful management of working capital to sustain growth and operations.
- High Employee Attrition Impacting Service Quality and Scalability: The healthcare industry often faces challenges with employee retention. High attrition rates among skilled Ayurvedic practitioners and support staff could lead to increased recruitment and training costs, potential disruptions in service delivery, and an impact on the consistency and quality of patient care, thereby affecting the company’s ability to scale effectively.
- Dependence on Brand Reputation in a Competitive and Unregulated AYUSH Market: KRM AYURVEDA’s success heavily relies on its brand reputation in a highly competitive and somewhat unregulated AYUSH market. The sector is characterized by numerous players and varying standards. Any adverse publicity, quality concerns, or changes in regulatory oversight could significantly impact the company’s brand image, patient trust, and market share.
Awaiting Live Subscription Updates
Subscription statistics will be updated here as soon as the IPO bidding commences and live data becomes available from official exchanges.
| Investor Category | Shares Reserved (Lakhs) | Shares Applied (Lakhs) | Subscription (Times) |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | – | – | – |
| Non-Institutional Investors (NII) | – | – | – |
| Retail Individual Investors (RII) | – | – | – |
| Total | – | – | – |
*This section will be populated with live subscription data once the IPO opens for bidding. GMP figures are unofficial and may vary; exchange data is more reliable.
How to Participate in the KRM AYURVEDA IPO
Investors keen on participating in the KRM AYURVEDA IPO can do so conveniently through the official Dhan Kirti IPO platform. Ensure your application is submitted before the subscription window officially closes to be considered for allotment.
